BLAINTRAVENOUSSOLUTION
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 3m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Octagam is an intravenous immune globulin (IVIG) derived from human plasma that provides passive immunization through antigen neutralization. It is used to treat primary immunodeficiency disorders, autoimmune conditions, and certain infectious diseases by supplying immunoglobulins to patients with deficient or dysregulated immune systems. The drug works by delivering pooled antibodies from multiple donors to restore immune function.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely in transition mode, preparing for generic/biosimilar entry and repositioning for niche or specialized segments.
Mechanism of Action
Pharmacologic Class:
Antigen Neutralization
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Started Jan 2026
183 enrolled
Multiple MyelomaSecondary Immunodeficiency
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Started Feb 2025
100 enrolled
Primary Immunodeficiency Diseases (PID)
Survey of Human Rabies Immune Globulin Safety in Children
Started Feb 2023
35 enrolled
RabiesRabies HumanRabies Virus Infection+1 more
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
Started Feb 2021
12 enrolled
Coronavirus Disease 2019 (COVID-19)
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
Started Dec 2020
24 enrolled
Primary Immune Deficiency
Worked on Octagam Immune Globulin (Human) at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.